Figure 1.
Treatment regimens in the groups of various patients. DAA, direct-acting antiviral; GLE/PIB, glecaprevir/pibrentasvir; SVR12, sustained virologic response at 12 weeks after the end of treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.